Other formats:
BibTeX
LaTeX
RIS
@article{1807995,
author = {Sponer, P. and Kucera, T. and Brtkova, J. and Urban, K. and Koci, Z. and Mericka, P. and Bezrouk, A. and Konradova, S. and Filipova, A. and Filip, S.},
article_location = {THOUSAND OAKS},
article_number = {10},
doi = {http://dx.doi.org/10.1177/0963689718794918},
keywords = {mesenchymal stromal cells; scaffold; bone defect; cell therapy},
language = {eng},
issn = {0963-6897},
journal = {Cell Transplantation},
note = {RIV/00216208:11130/18:10380944},
title = {Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects},
url = {https://journals.sagepub.com/doi/10.1177/0963689718794918},
volume = {27},
year = {2018}
}
TY - JOUR
ID - 1807995
AU - Sponer, P. - Kucera, T. - Brtkova, J. - Urban, K. - Koci, Z. - Mericka, P. - Bezrouk, A. - Konradova, S. - Filipova, A. - Filip, S.
PY - 2018
TI - Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects
JF - Cell Transplantation
VL - 27
IS - 10
SP - 1459-1468
EP - 1459-1468
PB - SAGE PUBLICATIONS INC
SN - 09636897
N1 - RIV/00216208:11130/18:10380944
KW - mesenchymal stromal cells
KW - scaffold
KW - bone defect
KW - cell therapy
UR - https://journals.sagepub.com/doi/10.1177/0963689718794918
N2 - This prospective study sought to evaluate the healing quality of implanted ultraporous beta-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received beta-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received beta-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts only (the control group C). Clinical and radiographic evaluations were scheduled at 6 weeks, 3, 6, and 12 months post-operatively, and performed at the most recent visit as well. All observed complications were recorded during follow-up to assess the use of an ultraporous beta-tricalcium phosphate synthetic graft material combined with expanded MSCs in bone defect repair. The resulting data from participants with accomplished follow-up were processed and statistically evaluated with a Freeman-Halton modification of the Fischer's exact test, a P < 0.05 value was considered to be significant. Whereas no significant difference was observed between the trial group A with beta-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs and control group C with cancellous impaction allografting in terms of the bone defect healing, significant differences were documented between the study group B with beta-tricalcium phosphate graft material only and control group C. Regarding adverse effects, six serious events were recorded during the clinical trial with no causal relationship to the cell product. beta-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs appears safe and promotes the healing of bone defects in a jeopardized and/or impaired microenvironment.
ER -
SPONER, P., T. KUCERA, J. BRTKOVA, K. URBAN, Z. KOCI, P. MERICKA, A. BEZROUK, S. KONRADOVA, A. FILIPOVA and S. FILIP. Comparative Study on the Application of Mesenchymal Stromal Cells Combined with Tricalcium Phosphate Scaffold into Femoral Bone Defects. \textit{Cell Transplantation}. THOUSAND OAKS: SAGE PUBLICATIONS INC, 2018, vol.~27, No~10, p.~1459-1468. ISSN~0963-6897. Available from: https://dx.doi.org/10.1177/0963689718794918.
|
